Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A CERA-ous Challenge to Amgen's EPO Franchise?

This article was originally published in RPM Report

Executive Summary

How serious is the follow-on biological challenge from Roche's CERA to Amgen Inc.'s $6 billion erythropoietin (Epogen) franchise? Serious enough to move Amgen from a growth favorite to a biotech bargain. Serious enough to threaten the ability of Amgen and Procrit manufacturer Johnson & Johnson Inc. to find new dollars in the EPO world market in 2009 and beyond.

You may also be interested in...



Best of the Blog: IN VIVO, April 2008

"Best of the Blog" is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In April: Televancin Delayed by Grassley's Ketek Data Integrity Rule; Diabetes Drug Development and Regulatory Risk: Why the Guidance May Be Good News; and Mircera: Bad for Patents, Good for Patients?

Best of the Blog: IN VIVO, April 2008

"Best of the Blog" is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In April: Televancin Delayed by Grassley's Ketek Data Integrity Rule; Diabetes Drug Development and Regulatory Risk: Why the Guidance May Be Good News; and Mircera: Bad for Patents, Good for Patients?

The Other Agency: CMS Shocks Wall Street-and Amgen Takes a Hit

Biotech investors are used to worrying about what FDA will or won't do to a blockbuster drug, especially in the current climate of drug safety hysteria. But Wall Street didn't expect the federal Medicare agency to get into the act.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS080082

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel